Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Docetaxel with or without Radium Ra 223 Dichloride in Treating Patients with Metastatic Castration-Resistant Prostate Cancer

Trial Status: active

This phase III trial studies docetaxel and radium Ra 223 dichloride to see how well it works compared with docetaxel alone in treating patients with prostate cancer that has spread to other places in the body, despite the surgical removal of the testes or medical intervention to block androgen production (metastatic castration-resistant). Chemotherapy drugs, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radium Ra 223 dichloride is a radioactive drug that is given through the vein and is taken up by bones after it is injected into the body. Radioactive drugs work by giving off energy, which is thought to kill the tumor cells and other cells that support the tumor cells after the cancer has spread to the bone. It is not known whether docetaxel with or without radium Ra 223 dichloride works better at treating metastatic castration-resistant prostate cancer.